Background: Postpartum hemorrhage is the leading cause of maternal mortality; uterineatony is the most important cause. Uterotonics are used to prevent uterine atony. Carbetocin,a synthetic anallague of oxytocin seems to be an effective and safe new drug for preventionof PPH after caesarean The Aim of Study:To find out the efficacy and safety of carbetocin over oxytocin for theprevention of PPH during caesarean section.Patients and Methods: A randomized-controlled trial was conducted in the Dept. of Obs &Gyane, Rangpur Medical College and Hospital, Rangpur, Bangladesh over a period of twelvemonths from June 2016 to June 2017. One hundred admitted patients undergoing cesareansection at term were randomized into two groups receiving either 10 IU oxytocin or 100 μgcarbetocin after caesarean section. Outcome measures such as primary PPH, massiveblood loss, need for additional uterotonic drug, additional blood transfusion as well as adverseeffects were all documented. Results: Massive blood loss occurred in 6% patients, blood transfusion needed in 20% patientsand additional uterotonic needed for 36% patients in Oxytocin group but in Carbetocin groupno massive blood lossoccurred, only 2%patients needed immediate blood transfusion and4% patients were required additional uterotonics. There were no major adverse effectsobserved in both the groups. No patients had developed PPH in carbetocin group. But 8%(4)patients had developed PPH in oxytocin group. Conclusion: Carbetocin appears to be an effective new drug than Oxytocin for the preventionof postpartum hemorrhage following caesarean section. Bangladesh J Obstet Gynaecol, 2018; Vol. 33(2) : 113-118
Background: Clinical course of ovarian tumours are amazingly quite and the malignant ones are often inoperable by the time they are diagnosed. Aim of this study was to look into any probable way of early diagnosis of ovarian tumour.Methods: This study was carried out at the Department of Obstetrics & Gynaecology of Rangpur Medical College Hospital, Rangpur from July 2012 to June 2014. In this study, total 31 cases were included. The findings were described as percentage of total. In addition, χ2 test & Pearson’s correlation coefficient ‘r’ test were also used.Results: Age range of all the cases was between 16 and 65 years. Among the 31 cases, benign cases were 77.41% and malignant were 22.59%. The highest incidence of benign case was observed around 35 years of age and for the malignant cases was above 60 years. Patients commonly presented with abdominal lump (83.87%), abdominal pain (83.87%) and dyspepsia (74.19%). Other presentations were weight loss (22.58%), rapid enlargement of growth (16.13%), sense of heaviness of abdomen (9.67%) and abdominal enlargement (3.23%). Histologically serous cystadenoma was 38.71%, dermoid cyst 22.58%, mucinous cystadenoma 16.13%, poorly differentiated adenocarcinoma 12.90%, serous cyst adenocarcinoma 6.45% and immature teratoma was 3.23%.Conclusion: This sample is too small to draw any conclusion. Yet, as it was found, the incidence of benign tumours rises with increasing age up to 40 years and thereafter it declines. Whereas, the incidence of malignant tumours are very low before 40 years and thereafter it increases gradually. Also, public awareness may be developed regarding a female, specifically above 40 years of age, if complaints of abdominal lump, abdominal pain or dyspepsia should be evaluated properly; this may help in early diagnosis of many malignant ovarian tumours.TAJ 2015; 28(1): 21-25
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.